Phase I study of KRP-AM1977X (Clinical pharmacological study)

KRP-AM1977X Phase I Clinical Study Pharmacokinetics and Safety in Patients with Renal Dysfunction

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080225074

Enrollment

Registered

2020-02-14

Start date

2014-11-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with renal dysfunction

Interventions

investigational material(s) Generic name etc : KRP-AM1977X INN of investigational material : lascufloxacin Therapeutic category code : 624 Synthetic antibacterials Dosage and Administration for Invest

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Person with BMI that is more than 18.5 but less than 30.0, etc.

Exclusion criteria

Exclusion criteria: Have a history of allergy or severe side effects to quinolone antibiotics.

Design outcomes

Primary

Measure	Time frame
pharmacokinetics pharmacokinetics	—

Secondary

Measure	Time frame
safety safety	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026